Global EGFR Mutation Test Market Professional Survey Report 2019

Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.   
Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period.

The global EGFR Mutation Test market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on EGFR Mutation Test volume and value at global level, regional level and company level. From a global perspective, this report represents overall EGFR Mutation Test market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of EGFR Mutation Test in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their EGFR Mutation Test manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott
Merck
Thermo Fisher Scientific
Illumina
BioMerieux
QIAGEN
Agilent Technologies
Hologic
Novartis
Roche
Genomic Health

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
DNA Sequencing
Kits

Segment by Application
Cancer Hospitals
Clinical Research Institutes